Chen Chen, Su Yingjun, Chen Jianwu, Song Yajuan, Zhuang Ran, Xiao Bo, Guo Shuzhong
Department of Plastic and Reconstructive Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
Department of Immunology, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
Exp Hematol. 2016 Jul;44(7):614-623.e3. doi: 10.1016/j.exphem.2016.04.002. Epub 2016 Apr 14.
For allogeneic hematopoietic stem cell transplantation (HSCT), the first key step is the engraftment of hematopoietic stem cells (HSCs) across the major histocompatibility complex (MHC) barrier. Intrabone bone marrow transplantation (IBBMT) could replace more recipient stromal cells with donor cells and facilitate allogeneic organ transplantation compared with the conventional intravenous approach. However, it remains unknown whether and how IBBMT reconstructs the immune microenvironment for allogeneic HSCs. We explored where the BM microenvironment changes by determining BM stromal cell chimerism and measuring the change in CXCL-12 expression and regulatory T cells in recipient BM. We found that most stromal cells were replaced by allogeneic cells in the injected BM, with higher expression of immune regulatory cytokines (interleukin-10) compared with the contralateral BM and the intravenous group BM. This difference was independent of injury caused by intrabone injection. Consistent with the microenvironment modification, the allogeneic the engraftment rate and reconstitution capacity of HSCs were enhanced in the injected BM compared with the contralateral BM and intravenous group BM. Surgical removal of the injected bone at 7 days rather than 21 days reduced the levels of allogeneic granulocytes and HSCs in the peripheral blood. In conclusion, IBBMT specially modifies stromal cells in the injected BM which provide immune protective cues that improve the engraftment of allogeneic HSCs in an early period.
对于异基因造血干细胞移植(HSCT),首要关键步骤是造血干细胞(HSCs)跨越主要组织相容性复合体(MHC)屏障实现植入。与传统静脉注射方法相比,骨内骨髓移植(IBBMT)能用供体细胞替代更多受体基质细胞,并促进异基因器官移植。然而,IBBMT是否以及如何重建异基因造血干细胞的免疫微环境仍不清楚。我们通过确定骨髓基质细胞嵌合情况以及测量受体骨髓中CXCL-12表达和调节性T细胞的变化,来探究骨髓微环境的改变位置。我们发现,注射部位骨髓中的大多数基质细胞被异基因细胞替代,与对侧骨髓和静脉注射组骨髓相比,免疫调节细胞因子(白细胞介素-10)表达更高。这种差异与骨内注射造成的损伤无关。与微环境改变一致,与对侧骨髓和静脉注射组骨髓相比,注射部位骨髓中异基因造血干细胞的植入率和重建能力增强。在第7天而非第